- KR₩42tn
- KR₩45tn
- KR₩4tn
Focus: AbbVie's tight grip on Humira market raises concerns about biosimilars
Brief: Celltrion Inc Receives Market Approval From South Korea's Ministry Of Food And Drug Safety For 'Eydenzelt,' Biosimilar Of Eyelea Drug
Brief: Celltrion Q1 Consolidated Operating Profit 15.4 Billion Won, Down 91.5% From Year Earlier
Brief: Celltrion To Cancel 176.5 Billion Won Worth Of Own Shares
Brief: Celltrion To Acquire 75 Billion Won Worth Of Own Shares
S.Korean shares hit 19-month high on biopharma, e-commerce boost
Brief: Celltrion To Acquire 207 Billion Won Worth Of Own Shares
Brief: Celltrion Q3 Consolidated Operating Profit 267.6 Billion Won, Up 25.2% From Year Earlier
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap
Brief: Celltrion Wins 423.6 Billion Won Order
Brief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion To Absorb Celltrion Healthcare Co
South Korea biopharma stocks jump on rising COVID cases
South Korea to expand tax breaks for biopharmaceuticals
Celltrion launches biosimilar of AbbVie's blockbuster drug Humira in US
Brief: Celltrion To Acquire 50 Billion Won Worth Of Own Shares
Sandoz launches rival version of AbbVie's arthritis drug Humira
Analysis: New Humira rivals likely to hit US market with small discounts in July
Brief: Celltrion To Acquire 50 Billion Won Worth Of Own Shares